Deprizine Side Effects
Generic name: ranitidine
Medically reviewed by Drugs.com. Last updated on Aug 28, 2022.
Note: This document contains side effect information about ranitidine. Some dosage forms listed on this page may not apply to the brand name Deprizine.
Applies to ranitidine: oral capsule, oral suspension reconstituted, oral syrup, oral tablet. Other dosage forms:
Serious side effects of Deprizine
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
- Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
- Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.
Other side effects of Deprizine
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-332-1088. You may also report side effects at https://www.fda.gov/medwatch.
For Healthcare Professionals
Applies to ranitidine: compounding powder, injectable solution, intravenous solution, oral capsule, oral granule effervescent, oral syrup, oral tablet, oral tablet effervescent.
The most commonly reported side effect for IM administration was injection site pain, and the most commonly reported side effects with IV administration were localized pain and burning.[Ref]
Uncommon (0.1% to 1%): Abdominal discomfort/pain, constipation, nausea, vomiting
Bradycardia, atrioventricular block, tachycardia, and asystole have occurred in H2 receptor antagonists.[Ref]
Frequency not reported: Loss of libido[Ref]
Headache may be related to administration of treatment.[Ref]
Very rare (less than 0.01%): Headache/severe headache[Ref]
Very rare (less than 0.01%): Musculoskeletal symptoms, arthralgia, myalgia[Ref]
Rare (0.01% to 0.1%): Transient and reversible changes in liver function tests, increased ALT levels
Hepatitis with/without jaundice were usually reversible.
ALT levels increased to at least 2 times the pretreatment levels in patients receiving high IV doses for at least 5 days.[Ref]
Rare (0.01% to 0.1%): Fever, malaise
Frequency not reported: Death[Ref]
Rare (0.01% to 0.1%): Hypersensitivity reactions
Rare (0.01% to 0.1%): Elevation in serum creatinine
Very rare (less than 0.01%): Acute interstitial nephritis[Ref]
Elevation in serum creatinine was usually slight, and typically normalized with continued treatment.[Ref]
Rare (0.01% to 0.1%): Bronchospasm
Rare (0.01% to 0.1%): Reversible blurred vision[Ref]
Leukopenia, granulocytopenia, and thrombocytopenia were usually reversible.[Ref]
Very rare (less than 0.01%): Gynecomastia[Ref]
Frequency not reported: Injection site pain, transient localized burning or itching[Ref]
More about Deprizine (ranitidine)
- Check interactions
- Latest FDA alerts (18)
- Dosage information
- During pregnancy
- Drug class: H2 antagonists
Related treatment guides
1. "Product Information. Zantac (ranitidine)." Glaxo Wellcome (2001):
2. "Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals (2002):
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. Cerner Multum, Inc. "Australian Product Information." O 0
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.